Evidence map›Paper›PMID 31028834›Full record

ReviewMolecular and cellular neurosciences2019

Cross talk between SOD1 and the mitochondrial UPR in cancer and neurodegeneration.

Maria Gomez, Doris Germain

Open access · greenAbstract readReview
In one paragraph

Review in Molecular and cellular neurosciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. From hemocuprein to CSRP: the many faces of Cu/Zn superoxide dismutase.Metallomics : integrated biometal science · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022
    Article
  15. Altered Mitochondrial Protein Homeostasis and Proteinopathies.Frontiers in molecular neuroscience · 2022
    Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Maria GomezIcahn School of Medicine at Mount Sinai, Tisch Cancer Institute, Department of Medicine, Division of Hematology/Oncology, New York, 10029, NY, USA.
Doris GermainIcahn School of Medicine at Mount Sinai, Tisch Cancer Institute, Department of Medicine, Division of Hematology/Oncology, New York, 10029, NY, USA. Electronic address: doris.germain@mssm.edu.
Icahn School of Medicine at Mount Sinai · US

Funding

Role of SOD1 in cancerR01CA172046 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GERMAIN, DORIS A · 2014 to 2018
$1.9M
NCI NIH HHS R01 CA172046
6 · The paper itself

Abstract

The mitochondrial unfolded protein response (UPR

Indexed as

Unfolded Protein ResponseAnimalsCell NucleusHumansMitochondriaNeoplasmsNeurodegenerative DiseasesOxidative StressSignal TransductionSuperoxide Dismutase-1Superoxide Dismutase-1ALSCancerEstrogen receptorMitochondriaNeurodegenerationROSSIRT3SOD1SOD2UPR(mt)

Identifiers

PMID31028834
PMCPMC6614005
OpenAlexW2942002421

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.